deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT03090100

A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis (ECLIPSE)

A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis

Sponsor: Janssen Research & Development, LLC

Conditions Psoriasis
Interventions Guselkumab Placebo Secukinumab
Updated 16 times since 2017 Last updated: Sep 6, 2019 Started: Apr 27, 2017 Primary completion: Aug 2, 2018 Completion: Sep 20, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Psoriasis, this trial is completed. The trial is conducted by Janssen Research & Development, LLC and has accumulated 16 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Apr 2017 – ~Jun 2017 · 2 months · monthly snapshot~Jun 2017 – ~Aug 2017 · 2 months · monthly snapshot~Aug 2017 – ~Oct 2017 · 2 months · monthly snapshot~Oct 2017 – ~Dec 2017 · 2 months · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Nov 2019 · 12 months · monthly snapshot~Nov 2019 – ~Jan 2021 · 14 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Nov 2019 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 11 earlier versions

  1. Nov 2018 — Nov 2019 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  2. Oct 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE3

  3. Sep 2018 — Oct 2018 [monthly]

    Active Not Recruiting PHASE3

  4. Aug 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE3

  5. Jul 2018 — Aug 2018 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  6. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE3

    Status: Active Not Recruiting → Recruiting

  7. Dec 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  8. Oct 2017 — Dec 2017 [monthly]

    Recruiting PHASE3

  9. Aug 2017 — Oct 2017 [monthly]

    Recruiting PHASE3

  10. Jun 2017 — Aug 2017 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  11. Apr 2017 — Jun 2017 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Janssen Research & Development, LLC
Data source: Janssen Research & Development, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ajax, Canada , Albuquerque, United States , Alcorcón, Spain , Alicante, Spain , Alpharetta, United States , Atlanta, United States , Austin, United States , Badalona, Spain , Barakaldo, Spain , Barcelona, Spain and 115 more locations